International journal of hematology-oncology and stem cell research最新文献

{"title":"Outcome of T-Lymphoblastic Leukemia-Lymphoma with Hyper C-VAD Regimen.","authors":"Nasrin Namdari, Elahe Ataei, Fatame Ghanbarian, Sezaneh Haghpanah, Maral Mokhtari","doi":"10.18502/ijhoscr.v19i4.19981","DOIUrl":"10.18502/ijhoscr.v19i4.19981","url":null,"abstract":"<p><p><b>Background:</b> T-cell lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) are aggressive diseases with dismal prognoses. <b>Materials and Methods:</b> All adult patients with T-ALL and T-LBL who were candidates for the Hyper-CVAD chemotherapy protocol were included. We evaluated overall survival and progression-free survival in 46 new cases. The T-ALL and T-LBL number of cases was 32 and 14, respectively. <b>Results:</b> Two- and 3-year OS were 41.8% (standard error (SE): 7%) and 27.8% (SE: 7%), respectively. Two- and 3-year PFS were 36.9% (SE: 7%) and 25.3% (SE: 7%), respectively. The only variable that had a significant relationship with the duration of PFS and OS was Allogenic SCT. Patients receiving Allogeneic SCT had longer survival time (2-year overall survival of 80% against 20%) (p˂0.001). <b>Conclusion:  </b>These data support the concept that Hyper-CVAD is not an appropriate and adequate regimen. We need new targeted agents in the T-ALL and T-LBL induction regimen while considering Allogeneic SCT as a Consolidation.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 4","pages":"332-337"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13135732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147847887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dysregulated Expression of miR-222 and miR-15a in Transfusion-Dependent Thalassemia: Associations with Torque Teno Virus and Cytomegalovirus Infections.","authors":"Mahdiyar Iravani Saadi, Nasrin Noshadi, Fakhroddin Hosseini, Soodabeh Zare, Ramin Yaghobi, Zahed Karimi, Zahra Ghahramani, Mani Ramzi","doi":"10.18502/ijhoscr.v19i4.19985","DOIUrl":"10.18502/ijhoscr.v19i4.19985","url":null,"abstract":"<p><p><b>Background:</b> Beta-thalassemia is a hereditary blood disorder characterized by reduced synthesis of the beta-globin chain. MicroRNAs (miRs) are small RNA molecules that regulate gene expression and have been implicated in beta-thalassemia. To explore dysregulated miR-222 and miR-15a expression in transfusion-dependent beta-thalassemia and assess their potential associations with Torque Teno Virus and cytomegalovirus infections. <b>Materials and Methods:</b> This study included 57 TDT patients registered at the Thalassemia Clinic affiliated with the Hematology Research Center, Shiraz, Iran. The expression levels of miR-222 and miR-15a were analyzed using the real-time SYBR Green PCR method. TTV and CMV infections were detected by analyzing the presence of their genomic DNA using an in-house semi-nested PCR protocol. <b>Results:</b> The expression level of miR-222 was significantly upregulated (47.5-fold, P≤0.001) in TDT patients compared to healthy controls. However, the expression of miR-15a in TDT patients was slightly decreased compared to healthy controls, but the difference was not statistically significant (P=0.193). TTV infection was observed in 21.1% of TDT patients, while CMV infection was detected in 5.2% of the patients. Although miR-222 and miR-15a gene expression levels were higher in TTV-positive patients compared to TTV-negative patients, the differences were not statistically significant (P=0.926 and P=0.243, respectively). <b>Conclusion:</b> MiR-222 was upregulated in TDT patients, but miR-15a did not show a significant difference. TTV and CMV infections were detected, but their association with miR expression was not significant, possibly due to the small sample size. Larger studies are needed for a more comprehensive evaluation.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 4","pages":"365-376"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13135744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147847786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Narrative Review of Advancements in Stem Cell Therapy: Adipose-Derived Stem Cells for Diabetic Foot Ulcer Treatment.","authors":"Prithiviraj Nagarajan, Mani Rajarathinam, Gayathiri Ekambaram, Leena Rajathy Port Louis, Ramachandran Kaliaperumal","doi":"10.18502/ijhoscr.v19i4.19987","DOIUrl":"10.18502/ijhoscr.v19i4.19987","url":null,"abstract":"<p><p>Diabetic foot ulcers (DFUs) are a severe complication of diabetes, with current standard care often failing to prevent chronic morbidity and amputation. This narrative review examines the therapeutic potential of adipose-derived stem cells (ADSCs) for DFUs treatment. ADSCs promote healing through paracrine secretion of growth factors, immunomodulation, and stimulation of angiogenesis, as demonstrated in promising preclinical and early clinical studies. We outline these mechanisms, discuss the emerging role of ADSC-derived exosomes as a potentially safer alternative, and summarize key clinical findings. However, significant challenges remain, including potential risks of tumorigenicity, donor cell variability, and a lack of standardized protocols. While ADSC therapy represents a highly promising regenerative approach for DFUs, its safety and efficacy must be firmly established through more rigorous preclinical studies and large -scale randomized controlled trails before broad clinical adoption. This review concludes that while ADSC therapy is a highly promising regenerative approach for DFUs, its translation to clinical practice necessitates further rigorous investigations to overcome existing translational barriers.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 4","pages":"388-398"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13135733/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147847903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Report of Granular Blasts in Adult B-Cell ALL: A Rare Morphological Mimic of AML.","authors":"Morteza Garmei, Arefeh Mazhari, Mohammad Hadi Sadeghian, Fatemeh Shams, Hossein Ayatollahi, Maryam Sheikhi, Elham Jafaei, Amirali Ayatollahi, Yasamin Minaeitorshizi","doi":"10.18502/ijhoscr.v19i4.19989","DOIUrl":"10.18502/ijhoscr.v19i4.19989","url":null,"abstract":"<p><p>Granular ALL is one of the uncommon morphological variants of acute lymphoblastic leukemia (ALL), characterized by cytoplasmic granules in lymphoid blasts. This rare morphological presentation may lead to diagnostic misinterpretation. Case reports of such presentations enhance understanding of disease biology and therapeutic considerations. Case presentation: A 22-year-old woman with Granular ALL has been discussed here. In the Peripheral blood smear (PBS) of this patient, cytoplasmic granules were identified in the cytoplasm of lymphoblasts. Further examinations were conducted on the bone marrow aspiration (BMA) sample of the patient, including karyotyping, flowcytometric and conventional molecular evaluations for ALL. The flow cytometric results were consistent with a diagnosis of B-ALL; the karyotyping analysis showed 47, XX, +17[4], and molecular findings revealed no detectable abnormalities. Conclusion: Due to the misdiagnosis of Granular ALL as AML, the identification of distinguishing diagnostic features of Granular ALL is clinically significant. In this context, flow cytometric, cytogenetic, and molecular findings are invaluable to distinguish between these two types of acute leukemia.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 4","pages":"424-428"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13135729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147847941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Interplay of Autoimmune Disease, Cancer, and Immunity: Current Understanding and Therapeutic Prospects.","authors":"Tayyab Shafiq, Syeda Mahnoor Bukhari, Arneeb Zahra, Hafiza Sana Mahek, Hira Tariq, Waseem Sajjad","doi":"10.18502/ijhoscr.v19i4.19986","DOIUrl":"10.18502/ijhoscr.v19i4.19986","url":null,"abstract":"<p><p><b>Background:</b> In light of chronic inflammation and dysregulated immune responses, autoimmune disorders and cancer are closely related. It is essential to comprehend how they interact in order to create immunotherapeutic techniques that work. <b>Materials and Methods:</b> The purpose of this review is to summarize the most recent research on the relationship between immunology, cancer, and autoimmune illnesses and to assess new treatment strategies that target each of these diseases. PubMed, MEDLINE, the Cochrane Library, Embase, and Scopus were used in a methodical search (2010-2023). Studies evaluating immunotherapy results, immunological processes, and cancer incidence in patients with autoimmune diseases were all eligible. Using random-effects meta-analysis, the data were examined. <b>Results:</b> A total of 78,456 patients from fifty-seven studies were examined. Patients with autoimmune diseases had a considerably higher risk of developing cancer (OR = 1.58; 95% CI: 1.42-1.76; p < 0.001), frequently as a result of immunosuppressive treatment and persistent inflammation. Among the common mechanisms were increased pro-inflammatory cytokines (TNF-α, IL-6) and dysregulation of immunological checkpoints (PD-1/PD-L1). Although cytokine blockers and checkpoint inhibitors have demonstrated effectiveness, they also carry significant hazards. <b>Conclusion:</b> The confluence of immune regulation, cancer, and autoimmunity brings to light both treatment possibilities and difficulties. Future studies should concentrate on tailoring immunotherapies to optimize their positive effects while reducing their negative ones.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 4","pages":"377-387"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13135730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147847864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Mini-Review on Fibroblast-Derived Exosomes as Wound Healing Stimulators.","authors":"Alireza Sadeghi Moghaddam Bijari, Mahdi Alijanianzadeh, Hoda Keshmiri Neghab, Mohammad Hasan Soheilifar","doi":"10.18502/ijhoscr.v19i3.19287","DOIUrl":"10.18502/ijhoscr.v19i3.19287","url":null,"abstract":"<p><p>The skin is a vital organ that plays a crucial role in healing disruptions and abnormalities. Cutaneous wound healing faces some obstacles in certain abnormalities, including in diabetic patients. Various therapeutic approaches have been explored to enhance healing and restore skin integrity. In recent years, exosomes have been introduced as a new cell-free therapy for wound healing. They are defined as naturally secreted nanovesicles released from most cell types into the extracellular space that can impact many targeted cells. In contrast to previous methods, exosomes have a longer half-life in target tissue and exert a more lasting effect. They also have fewer side effects thanks to their natural biological source. Exosomes derived from mesenchymal stem cells (MSCs) have been widely studied for their therapeutic potential, but those from other cell types, such as fibroblasts, remain less explored. This review aims to comprehensively evaluate existing research on the wound-healing effects of fibroblast-derived exosomes (FB-EXOs), highlighting their potential as a novel treatment strategy.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 3","pages":"237-247"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12630532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145589704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sweet's Syndrome as a Prodromal Manifestation of Acute Myeloid Leukemia.","authors":"Atefeh Rezaee, Tina Vosoughi, Mehran Hosseinzadeh, Mohammad Hossein Rastegar","doi":"10.18502/ijhoscr.v19i3.19290","DOIUrl":"10.18502/ijhoscr.v19i3.19290","url":null,"abstract":"<p><p>Sweet's syndrome is a rare dermatological condition characterized by a constellation of clinical features, including fever, neutrophilic leukocytosis, painful skin plaques, and dermal neutrophil infiltration. Various etiologies have been documented, encompassing both underlying diseases and pharmacological agents. We present a case involving a 35-year-old female patient who exhibited fever and progressive cutaneous lesions manifesting as a painful erythematous rash on the limbs and trunk. Initially misdiagnosed as seronegative lupus erythematosus, her condition did not improve. A skin biopsy revealed significant neutrophilic infiltration, and she subsequently developed leukocytosis, leading to a diagnosis of acute leukemia upon bone marrow examination. The patient was treated with chemotherapy, resulting in a relative improvement of her skin lesions.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 3","pages":"286-290"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12630367/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145590573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Efficacy, Safety, and Prognostic Value of Induction Chemotherapy in Patients with Acute Myeloid Leukemia: An Updated Meta-Analysis of a 5-Year Study.","authors":"I Made Adi Narendranatha Komara, Ketut Suega, Ni Made Renny Anggreni Rena, I Wayan Losen Adnyana","doi":"10.18502/ijhoscr.v19i3.19288","DOIUrl":"10.18502/ijhoscr.v19i3.19288","url":null,"abstract":"<p><p>Acute Myeloid Leukemia (AML) is a type of cancer that affects the bone marrow and blood. This study aims to conduct a five-year update on induction chemotherapy's efficacy, safety, and prognostic value in patients with AML. Based on the PRISMA 2020 guidelines, a systematic search was performed on online databases for relevant studies on complete remission with incomplete hematologic response (CRi), complete remission (CR), adverse events, and overall survival. The articles obtained were observational studies that met the inclusion and exclusion criteria. The quality of the studies was assessed using the Revised Cochrane's risk-of-bias tool. The analysis was conducted using Review Manager 5.4 and R Statistical Software 3.3. Thirteen clinical trial studies, involving 1,863 participants, were included in this survey. Based on the analysis, the CRi and CR levels, where each was obtained as a whole at 9% (random effect; 95%CI 6-13%; heterogeneity; 𝜏²<0.12; I²=35%), and 56% (random effect; 95%CI 43-69%; heterogeneity; 𝜏² <0.01; I²=88%). Gastrointestinal side effects, hepatotoxicity, nephrotoxicity, cardiotoxicity, and infection after induction chemotherapy in AML patients overall were 22% (random effect; 95%CI 10-44%; heterogeneity; 𝜏²<0.01; I²=89%), 8% (random effect; 95%CI 5-11%; heterogeneity; 𝜏²=0.62; I²=0%), 15% (random effect; 95%CI 4-44%; heterogeneity; 𝜏² <0.01; I²=89%), 7% (random effect; 95%CI 5 - 11%; heterogeneity; 𝜏²<0.01; I²=76%), and 20% (random effect; 95%CI 13-30%; heterogeneity; 𝜏²<0.01; I²=76%). Overall survival was 57% (random effect; 95%CI 43-71%; heterogeneity; 𝜏²<0.01; I²=86%). Peter's test showed a significant risk of publication bias. Induction chemotherapy is effective and improves outcomes in AML patients.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 3","pages":"248-260"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12630385/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145590387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Spectrum of Bosutinib Related Side Effects in a Patient of CML: A Case Report and Review of Literature.","authors":"Vishnu Sharma, Sidharth Mahajan, Vansh Bagrodia, Jahanvi Grover, Vaibhav Oberoi","doi":"10.18502/ijhoscr.v19i3.19291","DOIUrl":"10.18502/ijhoscr.v19i3.19291","url":null,"abstract":"<p><p>This case study outlines the complex treatment journey of a 53-year-old male diagnosed with Chronic Myeloid Leukemia (CML). Despite initial therapy with Imatinib and a subsequent switch to Dasatinib and then Bosutinib due to treatment resistance and adverse effects, the patient experienced multiple unexpected complications, including bilateral pleural effusions, pulmonary arterial hypertension, renal impairment, and neurological symptoms. Bosutinib was identified as the likely cause, leading to its discontinuation and transition to Nilotinib, which resulted in a sustained molecular response without further adverse events. Through this case report and literature review, we aim to expand the dimensions of the toxicity profile of bosutinib.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 3","pages":"291-295"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12630388/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145590407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Potential and Comparison of the Effects of Mummy on Mesenchymal Stem Cells Derived from Wharton's Jelly and Adipose Tissue Cultured with Human Fibroblasts.","authors":"Sepideh Hassanpour Khodaei, Leila Roshangar, Jafar Soleimani Rad, Shahnaz Sabetkam","doi":"10.18502/ijhoscr.v19i3.19282","DOIUrl":"10.18502/ijhoscr.v19i3.19282","url":null,"abstract":"<p><p><b>Background:</b> The wound healing process is a complex physiological mechanism that plays a crucial role in medical treatment. The slow healing rates and scar formation associated with many conventional therapies have prompted researchers to explore novel and more effective therapeutic options. This study investigates the effects of Mummy material, Wharton Jelly Stem Cells (WJSCs), and Adipose Stem Cells (ASCs) on the migration and proliferation of fibroblasts. <b>Materials and Methods:</b> This study demonstrated that fibroblast cells could successfully adhere to three-dimensional (3D) scaffolds within the specified microenvironment. ASCs were isolated from human adipose tissue, while WJSCs were obtained from women undergoing cesarean sections. We assessed the proliferation rate, migration, expression of fibronectin, collagen types I and III, and cell adhesion on polycaprolactone (PCL) scaffolds in the presence of Mummy material. <b>Results:</b> The findings highlighted the critical role of mummy material, ASCs, and WJSCs in promoting fibroblast migration and proliferation. The presence of these components significantly enhanced the expression of fibronectin (FN1) and collagen types I and III. Furthermore, the mummy material stimulated the proliferation of ASCs and WJSCs seeded on PCL scaffolds. Collectively, these results establish a valuable in vitro model for investigating wound healing mechanisms. <b>Conclusion:</b> The promising potential of utilizing Mummy material alongside stem cell-based therapies for enhancing wound healing is noteworthy.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 3","pages":"198-209"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12630408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145590518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}